Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Cancer Metastatic 1Hyperlipoproteinemia Type II 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Atherosclerosis 1

Interventions

Temozolomide 264Radiotherapy 119Bevacizumab 105Magnetic Resonance Spectroscopy 59Radiation 47pembrolizumab 30Irinotecan 28Surgical Procedures, Operative 23Lomustine 21Specimen Handling 19Nivolumab 19Radiosurgery 18Carmustine 18Aminolevulinic Acid 16Erlotinib Hydrochloride 15Drug Therapy 15Blood Specimen Collection 14Radiotherapy, Intensity-Modulated 13O(6)-benzylguanine 13Chemotherapy, Adjuvant 13Carboplatin 13Filgrastim 11Cyclophosphamide 11sargramostim 10poly ICLC 10atezolizumab 10Thalidomide 10Etoposide 10Ipilimumab 9Everolimus 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioblastoma × evolocumab × Clear all
NCT04937413 2024-06-25

The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Duke University

Phase EARLY_PHASE1 Completed
32 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡